---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-008527"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:08:51.179002+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics appoints Wendy L. Dixon, Ph.D. to board of directors

## Summary
- Dr. Dixon appointed effective after April 25, 2023 annual meeting, filling vacancy from Dr. Travis Mickle's resignation.
- She will serve as Class I director with term expiring at 2025 annual meeting.
- Initial option grant of 22,500 shares vesting over three years; annual retainer of $40,000.
- Dr. Dixon has over 40 years biopharma experience, previously CMO at Bristol Myers Squibb and SVP at Merck.
- No family relationships or reportable transactions under Item 404(a) of Regulation S-K.

## SEC filing metadata
- accession: 0001437749-23-008527
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923008527/0001437749-23-008527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923008527/zvra20230328_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-008527
- JSON: https://secwatch.observer/filing/0001437749-23-008527.json
- Plain text: https://secwatch.observer/filing/0001437749-23-008527.txt

## Key facts
- Executive change
  Travis Mickle resigned as Director at ZEVRA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Director
  source text: to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923008527/0001437749-23-008527-index.htm
- Executive change
  Wendy L. Dixon was appointed as Director at ZEVRA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Wendy L. Dixon, Ph.D. to serve as a director of the Company, effective immediately following the conclusion of the Company’s 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting") to be held on April 25, 2023, to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923008527/0001437749-23-008527-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.